Home>Topics>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals ALNY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Alnylam brings in news management talent

      Headlines

      Mon, 15 Sep 2014

      Alnylam ( ALNY -2.3% ) hires three new executives . It appoints Karen Anderson as SVP, Chief HR Officer. She joins the firm from Biogen

    2. Tekmira: Much More Than An Ebola Treatment

      Headlines

      Sun, 14 Sep 2014

      By Saul Markman : [Originally published 8/20/2014] Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR ) has been in the news recently as one of the leaders in developing a treatment for the Ebola Virus. It is a Vancouver based, publicly traded company. Because of the recent Ebola outbreak, Tekmira’s

    3. Gilead: Let's Make A Deal

      Headlines

      Thu, 28 Aug 2014

      By Small Pharma Analyst : Gilead Sciences (NASDAQ: GILD ) is on its way to becoming the second-largest pharmaceutical company in the US, perhaps even doing so this year. Gilead's growth has been nothing short of astounding, as it has transitioned in the past two years from a solid, medium-sized ...

    4. Alnylam receives NOA for RNAi-mediating molecules

      Headlines

      Wed, 20 Aug 2014

      The USPTO issues a Notice of Allowance to Alnylam Pharmaceuticals ( ALNY -0.5% ) for claims in the Tuschl et al. patent application 13/725,262. The 262 patent application includes claims directed

    5. Alnylam Pharmaceuticals Has Plenty On Its Plate

      Headlines

      Sat, 9 Aug 2014

      sector since the spring of this year, leading to unimpressive performance for leading RNAi companies Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Isis Pharmaceuticals (NASDAQ: ISIS ). I won't try to argue that valuations didn't get overheated

    6. Alnylam's 2Q as Expected; Pipeline Progress Continues

      Commentary

      Fri, 8 Aug 2014

      Alnylam Pharmaceuticals reported second-quarter results that were largely consistent with our expectations, and we're maintaining our $66 fair value

    7. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

      Stock Reports

      Fri, 8 Aug 2014

      of options issued as a percentage of shares outstanding, putting shareholders at risk for future dilution. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class

    8. ALNY ’s Q1 as Expected; Strategic Deals and Pipeline Progress Underpin Improving Moat Trend

      Commentary

      Fri, 9 May 2014

      We're maintaining our $66 fair value estimate for Alnylam Pharmaceuticals after first-quarter results that were consistent with our expectations. While Alnylam continued to advance its broad RNAi pipeline

    9. I have orders in for....

      Commentary

      Sat, 8 Mar 2014

      Orders are in for the following; PRAN ARWR RLYP ALNY I have done some work looking at the newest holdings in both BIPIX and FBIOX, both great BIO TECH funds. My orders are based

    10. Maintaining Our Alnylam Fair Value as Lead Program Approaches Late-Stage Trials

      Commentary

      Fri, 8 Nov 2013

      We're maintaining our $42 fair value estimate for Alnylam Pharmaceuticals following third-quarter results that were in line with our expectations. Early in the third quarter, positive data for ALN-TTRsc

    « Prev123Next »
    Content Partners